Literature DB >> 15459533

Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women.

Ralph M Trüeb1.   

Abstract

BACKGROUND: Finasteride, an inhibitor of type 2 5alpha-reductase, inhibits conversion of testosterone to dihydrotestosterone, resulting in a decrease in serum and scalp dihydrotestosterone levels believed to be pathogenic in androgenetic alopecia. Oral finasteride has been shown to be effective in the treatment of hair loss in men, while its efficacy in women has remained controversial.
METHODS: 5 postmenopausal women without clinical or laboratory signs of hyperandrogenism were given 2.5 or 5 mg/day oral finasteride for the treatment of pattern hair loss. Efficacy was evaluated by patient and investigator assessments, and review of photographs taken at baseline and at months 6, 12 and 18 by an expert panel.
RESULTS: Finasteride treatment improved scalp hair by all evaluation techniques. The patients' self-assessment demonstrated that finasteride treatment decreased hair loss, increased hair growth and improved appearance of hair. These improvements were confirmed by investigator assessment and assessments of photographs. No adverse effects were noted.
CONCLUSIONS: Oral finasteride in a dosage of 2.5 mg/day or more may be effective for the treatment of pattern hair loss in postmenopausal women in the absence of clinical or laboratory signs of hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459533     DOI: 10.1159/000079890

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  15 in total

1.  Efficacy of Finasteride 1.25 mg on Female Pattern Hair Loss; Pilot Study.

Authors:  Won-Jeong Kim; Margaret Song; Hyun-Chang Ko; Byung-Soo Kim; Moon-Bum Kim
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

2.  Contraindicated use of 5-alpha-reductase inhibitors in women.

Authors:  Martina Teichert; Eugene van Puijenbroek; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2016-09-30       Impact factor: 4.335

Review 3.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

Review 4.  Androgenetic Alopecia: An Update of Treatment Options.

Authors:  Yanna Kelly; Aline Blanco; Antonella Tosti
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

5.  Precision Medicine and the Practice of Trichiatry: Adapting the Concept.

Authors:  Ralph M Trüeb; Vicky M L Jolliffe; Antonia Fellas Régnier; Hudson Dutra Rezende; Sergio Vañó-Galván; Daisy Kopera; Demetrios Ioannides; Maria Fernanda Reis Gavazzoni Dias; Melanie Macpherson; Aida Gadzhigoroeva; Julya Ovcharenko; Won-Soo Lee; Sundaram Murugusundram; Sotaro Kurata; Mimi Chang; Chuchai Tanglertsampan
Journal:  Skin Appendage Disord       Date:  2019-08-20

Review 6.  Female pattern hair loss.

Authors:  Ingrid Herskovitz; Antonella Tosti
Journal:  Int J Endocrinol Metab       Date:  2013-10-21

Review 7.  Female pattern hair loss: current treatment concepts.

Authors:  Quan Q Dinh; Rodney Sinclair
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 8.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29

Review 9.  Pharmacologic interventions in aging hair.

Authors:  Ralph M Trüeb
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

10.  Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women.

Authors:  R Oliveira-Soares; J Maia E Silva; M Peres Correia; Marisa C André
Journal:  Int J Trichology       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.